Bora CDMO Bora CDMO

X

Find the latest Drugs in Development and Pipeline Prospector News of Kancera.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Kancera
Sweden Flag
Country
Country
Sweden
Address
Address
Karolinska Institutet Science Park Banvaktsvägen 22 SE-171 48 Solna
Telephone
Telephone
+46 (0)850 12 60 80
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Kancera plans a Phase II trial of its fractalkine receptor inhibitor KAND567 to prevent hyperinflammation in COVID-19 patients before they develop acute respiratory distress syndrome.


Lead Product(s): KAND567

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 20, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY